The Effect of Aspirin on the Prevention of Pro-thrombotic States in Hospitalized COVID-19 Patients : Systematic Review
Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net..
INTRODUCTION: Thromboembolic events are one of the important complications in COVID-19 patients, especially in severe cases. Aspirin affects platelet function by irreversibly inhibiting cyclooxygenase activity, reducing the risk of thrombosis. The current systematic review aimed to evaluate aspirin's effectiveness in preventing pro-thrombotic states in COVID-19 hospitalized patients.
METHODS: The systematic search was done in PubMed/Medline, EMBASE, and Medrxiv until September 27, 2021. The following keywords were used: "COVID-19", "SARS-CoV-2", "2019 Novel Coronavirus", "Aspirin," and "Acetylsalicylic Acid.".
RESULTS: Twelve studies were included. In COVID-19 patients, aspirin can reduce CRP, IL-6 levels, and platelet aggregation by inhibiting thromboxane A2. It can also improve antiviral immunity by hindering the biosynthesis of prostaglandins and lipoxin. Eight out of twelve articles indicated that aspirin provided a beneficial effect on COVID-19. Most studies consider lowered mechanical ventilation needs, ICU admission, illness severity, overt thrombosis, and clinical outcomes in COVID-19 patients receiving aspirin.
CONCLUSION: Aspirin as an antiplatelet and anti-inflammatory agent may reduce the mortality rates in hospitalized patients with severe COVID-19. Further observational studies are necessary to determine the effect of aspirin on the prevention of pro-thrombotic states in hospitalized COVID- 19 patients.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2022 |
---|---|
Erschienen: |
2022 |
Enthalten in: |
Zur Gesamtaufnahme - volume:20 |
---|---|
Enthalten in: |
Cardiovascular & hematological agents in medicinal chemistry - 20(2022), 3 vom: 06., Seite 189-196 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Abdi, Masoumeh [VerfasserIn] |
---|
Links: |
---|
Anmerkungen: |
Date Completed 23.09.2022 Date Revised 07.12.2022 published: Print Citation Status MEDLINE |
---|
doi: |
10.2174/1871525720666220401102728 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM338966765 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM338966765 | ||
003 | DE-627 | ||
005 | 20231226001845.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231226s2022 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.2174/1871525720666220401102728 |2 doi | |
028 | 5 | 2 | |a pubmed24n1129.xml |
035 | |a (DE-627)NLM338966765 | ||
035 | |a (NLM)35366783 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Abdi, Masoumeh |e verfasserin |4 aut | |
245 | 1 | 4 | |a The Effect of Aspirin on the Prevention of Pro-thrombotic States in Hospitalized COVID-19 Patients |b Systematic Review |
264 | 1 | |c 2022 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 23.09.2022 | ||
500 | |a Date Revised 07.12.2022 | ||
500 | |a published: Print | ||
500 | |a Citation Status MEDLINE | ||
520 | |a Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net. | ||
520 | |a INTRODUCTION: Thromboembolic events are one of the important complications in COVID-19 patients, especially in severe cases. Aspirin affects platelet function by irreversibly inhibiting cyclooxygenase activity, reducing the risk of thrombosis. The current systematic review aimed to evaluate aspirin's effectiveness in preventing pro-thrombotic states in COVID-19 hospitalized patients | ||
520 | |a METHODS: The systematic search was done in PubMed/Medline, EMBASE, and Medrxiv until September 27, 2021. The following keywords were used: "COVID-19", "SARS-CoV-2", "2019 Novel Coronavirus", "Aspirin," and "Acetylsalicylic Acid." | ||
520 | |a RESULTS: Twelve studies were included. In COVID-19 patients, aspirin can reduce CRP, IL-6 levels, and platelet aggregation by inhibiting thromboxane A2. It can also improve antiviral immunity by hindering the biosynthesis of prostaglandins and lipoxin. Eight out of twelve articles indicated that aspirin provided a beneficial effect on COVID-19. Most studies consider lowered mechanical ventilation needs, ICU admission, illness severity, overt thrombosis, and clinical outcomes in COVID-19 patients receiving aspirin | ||
520 | |a CONCLUSION: Aspirin as an antiplatelet and anti-inflammatory agent may reduce the mortality rates in hospitalized patients with severe COVID-19. Further observational studies are necessary to determine the effect of aspirin on the prevention of pro-thrombotic states in hospitalized COVID- 19 patients | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Systematic Review | |
650 | 4 | |a Aspirin | |
650 | 4 | |a COVID-19 | |
650 | 4 | |a SARS-COV-2 | |
650 | 4 | |a acetylsalicylic acid | |
650 | 4 | |a pro-thrombotic | |
650 | 4 | |a thrombosis | |
650 | 7 | |a Antiviral Agents |2 NLM | |
650 | 7 | |a Interleukin-6 |2 NLM | |
650 | 7 | |a Lipoxins |2 NLM | |
650 | 7 | |a Platelet Aggregation Inhibitors |2 NLM | |
650 | 7 | |a Prostaglandins |2 NLM | |
650 | 7 | |a Thromboxane A2 |2 NLM | |
650 | 7 | |a 57576-52-0 |2 NLM | |
650 | 7 | |a Prostaglandin-Endoperoxide Synthases |2 NLM | |
650 | 7 | |a EC 1.14.99.1 |2 NLM | |
650 | 7 | |a Aspirin |2 NLM | |
650 | 7 | |a R16CO5Y76E |2 NLM | |
700 | 1 | |a Lamardi, Zahra Hoseini |e verfasserin |4 aut | |
700 | 1 | |a Shirjan, Fatemeh |e verfasserin |4 aut | |
700 | 1 | |a Mohammadi, Leila |e verfasserin |4 aut | |
700 | 1 | |a Abadi, Sahel Shafiee Dolat |e verfasserin |4 aut | |
700 | 1 | |a Massoudi, Nilofar |e verfasserin |4 aut | |
700 | 1 | |a Zangiabadian, Moein |e verfasserin |4 aut | |
700 | 1 | |a Nasiri, Mohammad Javad |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Cardiovascular & hematological agents in medicinal chemistry |d 2006 |g 20(2022), 3 vom: 06., Seite 189-196 |w (DE-627)NLM161201482 |x 1875-6182 |7 nnns |
773 | 1 | 8 | |g volume:20 |g year:2022 |g number:3 |g day:06 |g pages:189-196 |
856 | 4 | 0 | |u http://dx.doi.org/10.2174/1871525720666220401102728 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 20 |j 2022 |e 3 |b 06 |h 189-196 |